Cardiac glycosides sales in South Korea are expected to decline steadily from 619.3 million won in 2024 to 609.4 million won by 2028. This represents a year-on-year decrease of 0.4% in 2025, 0.4% in 2026, 0.4% in 2027, and 0.4% in 2028. The Compound Annual Growth Rate (CAGR) over the next five years is projected to be approximately -0.4%. The sales in 2023 stood at 621 million won, indicating a consistent downward trend through the forecast period.
Future trends to watch for include advancements in alternative cardiac therapies, regulatory changes, and increasing competition from generic drugs, which could further impact the market for cardiac glycosides in South Korea.